Description |
APD125, an orally active compound, is developed for the treatment of insomnia. It is a highly selective antagonist at the 5-HT2A serotonin receptor. It increases non-REM sleep, the most restorative phase of the sleep cycle, without sacrificing REM or dream sleep.
APD125 works through a mechanism of action that is different from currently marketed drugs.
|
